



Spasticity Recommended Course Track

Tuesday, September 17, 2019: 1:00 pm – 5:00 pm

Ultrasound Symposium: Neuromuscular Ultrasound – Hands-on Ultrasound Training Course Part I

Katharine E. Alter, MD; Heakyung Kim, MD; David Cancel, MD

Wednesday, September 18, 2019: 1:00 pm – 5:00 pm

Neuromuscular Ultrasound - Hands-on Ultrasound Training Course Part II

Katharine E. Alter, MD; Heakyung Kim, MD; David Cancel, MD

Thursday, September 19, 2019: 7:00 am – 8:00 am

SYMP04 - SPASTIC MUSCLE IN CEREBRAL PALSY: CONTRACTURE, BOTULINUM TOXIN A, AND FUTURE DIRECTIONS

Jason J. Howard, BEng, MD, FRCSC; Kerr Graham, MD, MD, FRCS (Ed), FRACS; Tandy Hastings-Ison, PhD, BAppSci(Physio); Walter Herzog, PhD

Thursday, September 19, 2019: 6:30 pm – 8:00 pm

Wine and Cheese Poster and Exhibit Review

Sponsored by: Medtronic

T-F-SP01 - The Immediate Effects of Electroacupuncture On Gastrocnemius Muscle Tone Of Children With Spastic Cerebral Palsy

Jia Feiyong, M.D,PhD; Wang Lili, MS; Shan Ling, MS; Du Lin, MS; Zhang Yu, MD, PhD

T-F-SP02 - Botulinum Toxin And Casting May Delay Or Prevent Surgery In Spastic Hemiplegic Cerebral Palsy

Stephen T. Gates, MD; Robert Wimberly, MD; Anthony Riccio, MD; Mauricio Delgado, MD; Chan-Hee Jo, PhD

T-F-SP03 - Assessing Correlation Between Opening Pressure Values During Intrathecal Baclofen Test Dose With Post-Procedure Complications

Sara Cartwright, MD; Douglas G. Kinnett, MD, MD; Marina Ma, MD; Julie Estenfelder, BSN

T-F-SP04 - Impact Of Intrathecal Baclofen On Growth In Children With Spasticity

Amy L. Kaye, PhD

T-F-SP05 - Intrathecal Baclofen Therapy In Children: Impact On Quality Of Life And Caregiver Burden

Kirsty Stewart, PhD; Jenny Lewis, PT; Gavin Hutana, BA, MBBS

T-F-SP06 - Impact of Occupational Therapy on Selfcare Following Selective Dorsal Rhizotomy

Heather Forst, OTR/L; Kathleen M. Vonderhaar, MD; Tonye Sylvanus, MD; Nanette Aldahondo, MD; Angela Sinner, DO

T-F-SP07 - Long-Term Improvement on Gmfcs Level of Patients with Cerebral Palsy Treated By An Integrated Approach Of Repeated Botulinum Toxin-A Injections

Nigar Dursun, MD; Merve Akyuz, MD; Tugba Gokbel, MD; Melike Akarsu, MSc; Cagla Karacan, PhD; Erbil Dursun, MD

T-F-SP08 - Gross Motor Function Levels In Bilateral Spastic Cerebral Palsy from 4 to 25 Years of Age With And Without Early Selective Dorsal Rhizotomy A Population Based Study

Annika Lundkvist Josenby, PhD; Ann I. Alriksson-Schmidt, PhD; Lena Westbom, PhD

T-F-SP09 - Abobotulinumtoxina, Onabotulinumtoxina and Incobotulinumtoxina Neurotoxin Content And Activity: Potential Implications For Duration Of Efficacy In Pediatric Patients

Keith Foster, PhD; Malgorzata Field, MSc; Andrew Splevins, PhD; Marcel Van Der Schans, PhD; Jan Langenberg, PhD; Daan Noort, PhD; Philippe Picaut, PharmD

T-F-SP10 - A Randomized Controlled Study Of Virtual Reality For Pain Management During Botulinum Toxin Injections For Spasticity Management

Kristin Frenn, MPH; Lisa Lykken, BS; Elana Abelson, BA; Andrina MacDonald; Dalberg Todd, DO; Shannon Wier, BA; Elizabeth Jensen, BA; Frank Symons, PhD; Chantel Barney, PhD

T-F-SP11 - Comparison Of Frequency Of Surgeries And Botulinum Toxin Injections In Children With Cerebral Palsy Between Two Countries

Ira F. Jeglinsky, PhD; Reidun Jahnsen, PhD; Ann I. Alriksson-Schmidt, PhD; Gunvor L. Klevberg, PhD; Sonja Elkjær, MS; Matti Ahonen, MD, PhD

T-F-SP12 - National Collaboration for Selective Dorsal Rhizotomy (Sdr) Outcomes In Australia

Jenny Lewis, PT; Simon P. Paget, MA (Cantab), MBBS, MRCPCH(UK), FAFRM, FRACP; Natasha Bear, MSc; Felicity Baker, PT; Olivia Lee, MBBS, FRACP; Kim McLennan, MBBS, FRACP, FAFRM; Emma Richardson, MBBS; Adam Scheinberg, MBBS, FRACP, FAFRM, MMED; Nadine Smith, PT; Pam Thomason, B Phyt, M Physio; Andrew Tidemann, MBBS, FRACP; Meredith Wynter, PT; Adam Fowler, MBBS, FRACP

T-F-SP13 - Active And Passive Goal Achievement After Single-Event Multilevel Chemoneurolysis In Adults With Cerebral Palsy

Sangjee Lee, MS; Amber Newell, CPNP, OTR/L; Heakyung Kim, MD

T-F-SP14 - Selective Motor Fasciculotomy As An Adjunct In The Management Of Cerebral Palsy Children With Lower Limb Spasticity

Aniruddh K. Purohit, Sr., MD; Pavan Kumar Rathna, MD

Friday, September 20, 2019: 7:00 am – 8:00 am

BRK11 - BOTULINUM NEUROTOXIN UPDATES

Mark Gormley, MD; John Fox, DO; Kathleen M. Vonderhaar, MD

-or-

CC03 - A CURRENT CONTROVERSY: DOES SELECTIVE DORSAL RHIZOTOMY IMPROVE LONG-TERM FUNCTION

Freeman Miller, MD; Tom Novacheck, MD; Kristina Tedroff, MD, PhD

Friday, September 20, 2019 – 10:30 am – 12:15 pm

FREE PAPER SESSIONS

F. Tone Management

F4. SARCOPENIA, BOTULINUM TOXIN A AND CEREBRAL PALSY: A SYSTEMATIC REVIEW.

Kerr Graham, MD, MD, FRCS (Ed), FRACS; Iqbal Multani, MD; Tandy Hastings-Ison, PhD, BAppSci(Physio); Jason J. Howard, BEng, MD, FRCSC; Walter Herzog, PhD

F5. BOTULINUM TOXIN-A FOR CHRONIC PAIN IN SPASTIC CEREBRAL PALSY: A RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLINDED TRIAL

Dan N. Jacobson, MD; Kristina Löwing, PhD; Kjell Kullander, MD; Britt-Marie Rydh-Berner, PT; Malin Ljung, RN; Kristina Tedroff, MD, PhD

F7. BOTULINUM TOXIN-A TREATMENT IN CHILDREN WITH SPASTIC CEREBRAL PALSY: DIFFERENTIAL EFFECTS ON GAIT KINEMATICS BASED ON AGE AND LEVEL OF SEVERITY

Annet J. Dallmeijer, PhD; Kim van Hutten, MSc; Marjolein van der Krogt, PhD; Annemieke I. Buizer, MD PhD

F8. RETROSPECTIVE SURVEY OF PREDICTING FACTORS FOR SPASTICITY REDUCING INJECTIONS WITH BOTULINUM NEURO TOXIN IN THE UPPER LIMBS IN CHILDREN WITH CP.

Jenny Hedberg-Graff, MSc; Lena K. Krumlinde-Sundholm, PhD; Nicklas Philström, BS

F9. OUTCOMES OF THE FIRST-IN-HUMAN STUDY WITH A RECOMBINANT BOTULINUM TOXIN E (RBONT-E): SAFETY AND PHARMACODYNAMIC PROFILE OF RBONT-E COMPARED WITH ABOBOTULINUM TOXIN A

Laurent Pons, PhD; Claire Vilain, MD; Philippe Picaut, PharmD

F10. LONG-TERM SAFETY AND EFFICACY OF OPEN-LABEL ON ABOBOTULINUM TOXIN A FOR THE TREATMENT OF LOWER LIMB SPASTICITY IN CHILDREN WITH CEREBRAL PALSY

Jill Meilahn, DO; Heakyung Kim, MD; Brad Racette, MD; Fatma Gul, MD; Henry G. Chambers, MD; Emily McCusker, PhD; Kayla Chen, PhD; Rozalina Dimitrova, MD, MPH

Friday, September 20, 2019 – 12:15 pm - 1:15 pm

Non CME Luncheon Options

IPSEN Presentation Theatre: Dysport® (abobotulinumtoxinA) in the Treatment of Lower Limb Spasticity in Pediatric Patients 2 Years of Age and Older

Presenter: Mark E. Gormley, MD

Friday, September 20, 2019 – 4:30 pm - 6:30 pm

IC20 - MANAGEMENT OF DIFFICULT CLINICAL PRESENTATIONS OF HYPERTONIA AND COMPLEX MOVEMENT DISORDERS IN CHILDREN WITH DISABILITIES

Mark Gormley, MD; Tim Feyma, MD; Peter D. Kim, MD

-or-

IC21 - MUSCULOSKELETAL ADAPTATIONS TO SPASTICITY - IMPLICATIONS FOR CLINICIANS

N. Susan Stott, MBChB PhD FRACS; Jane Valentine, FRACP; Sian Williams, PhD; Richard L. Lieber, PhD

-or-

IC25 - LONG-TERM EFFECTS OF SELECTIVE DORSAL RHIZOTOMY (SDR) FOR INDIVIDUALS WITH CEREBRAL PALSY IN DEVELOPED (USA) AND DEVELOPING (SOUTH AFRICA) COUNTRIES

Tom Novacheck, MD; Nelleke G. Langerak, PhD; Robert P. Lamberts, PhD, FECSS; Marcie Ward, MD

Saturday, September 21, 2019: 8:15 am - 9:45 am

SYMP36 - INTEGRATED MANAGEMENT USING BOTULINUM TOXIN-A FOR HYPERTONIA IN CHILDREN WITH CEREBRAL PALSY

Nigar Dursun, MD; JORGE Carranza-del Rio, MD; Martin Bonikowski, MD; Ana Carolina de Campos, PhD, PT